Test Price
2,800 AED✅ Home Collection Available
G6PC2 Gene Hyperinsulinaemia Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This ISO-accredited genetic test delivers 99.9% diagnostic sensitivity for G6PC2-related congenital hyperinsulinism, supported by mandatory pre-test genetic counselling, VIP cold-chain home phlebotomy, and post-test clinical guidance from DHA-licensed clinicians. Direct insurance billing available via WhatsApp.
Test Overview & Methodology
The G6PC2 NGS test screens the full coding region of the G6PC2 gene to identify pathogenic variants linked to congenital hyperinsulinism (CHI), providing a molecular diagnosis that guides diazoxide therapy, dietary management, and family cascade screening. Next Generation Sequencing with Sanger confirmation ensures 99.9% analytical sensitivity and specificity.
| Feature | Our G6PC2 NGS Test | Standard Biochemical Workup |
|---|---|---|
| Precision | 99.9% analytical sensitivity & specificity (ISO 9001:2015 lab) | Variable; relies on 72‑h fasting glucose/insulin ratio |
| Method | Next Generation Sequencing (NGS) with Sanger confirmation | Plasma glucose & insulin, C‑peptide; indirect functional assay |
| Turnaround | 21–28 calendar days | Results in 72 hours; may require repeat fasting |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics (License No. 9294403), I confirm that this molecular test provides definitive aetiological classification for hyperinsulinaemic hypoglycaemia, enabling tailored therapy and reducing the risk of unnecessary surgical intervention. Results must always be integrated with clinical and biochemical findings.” – Lina Osama Zaki Quteineh
Important Medication Advisory
Never alter or discontinue prescribed diazoxide, octreotide, or any other glucose-regulating therapy without direct consultation with your treating endocrinologist. Sudden cessation may precipitate severe hypoglycaemic episodes requiring emergency intervention.
Exclusion Criteria & Emergency Indicators
- Exclusion: Inability to provide 3 mL peripheral blood (paediatric/adult); known haematological disorder compromising DNA quality.
- Red Flag: If you experience hypoglycaemic seizure, loss of consciousness, or severe sweating after prolonged fasting, seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What is the G6PC2 NGS test, and who should consider it?
This test identifies G6PC2 gene mutations linked to congenital hyperinsulinism for precise blood glucose management. It is recommended for individuals with documented non-ketotic hypoglycaemia, family history of CHI, or unclear response to diazoxide. Ordering specialists include Endocrinologists, Diabetologists, and Clinical Geneticists (DHA‑licensed).
2. How is the test performed, and what sample is needed?
A single blood draw (3 mL whole blood), one drop of blood on an FTA card, or previously extracted DNA is acceptable. Our VIP mobile phlebotomy team collects the sample at home under cold-chain conditions, following mandatory pre‑test genetic counselling to document family pedigree.
3. What is the turnaround time, and how will I receive results?
Results are available within 21–28 calendar days from sample collection. You will receive a secure digital report via WhatsApp or email, followed by a telephonic consultation with a DHA-licensed clinician to explain the findings and recommend next steps.
4. Does insurance cover this genetic test?
We offer direct insurance billing for most UAE health insurance plans. Please share your policy details via WhatsApp at +971 54 548 8731 to verify coverage and obtain a pre-authorization letter before sample collection.
5. What does a positive result mean for my family?
A pathogenic variant in G6PC2 confirms a molecular diagnosis of congenital hyperinsulinism and enables predictive testing for at-risk relatives. Cascade screening is recommended for first-degree family members, accompanied by genetic counselling to discuss inheritance patterns and clinical surveillance options.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance Framework
This laboratory operates under DHA Facility License No. 1143 and fully complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of genomic and health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating telemedicine, digital health records, and electronic communication of diagnostic results.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring clinical safety, informed consent, and accountability in diagnostic procedures.
- ISO 9001:2015 quality management certification (Cert: INT/EGQ/2509DA/3139) for laboratory processes.
All genomic sequence data is encrypted at rest and in transit, stored on secure servers within the UAE, and accessible only to authorized clinical personnel under strict confidentiality agreements.
Clinical & Logistical Metadata
| Test Name | G6PC2 Gene Hyperinsulinaemia Genetic Test (NGS with Sanger Confirmation) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 calendar days |
| Sample Type / Matrix | Whole Blood (3 mL), FTA Card Blood Spot, or Extracted DNA |
| Methodology Used | Next Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | E16.1 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians